WallSt Focus
Total 414 Posts
Charge Enterprises Reports Record Infrastructure Backlog Surpassing $100 Million and Reaffirms Growth Strategy
Charge Enterprises, Inc. (Nasdaq: CRGE) today reported record backlog after the close of the first quarter 2023 and reaffirmed its commitment to pursuing growth within the EV charging infrastructure sector.
Charge Enterprises Sets Date for 2023 First Quarter Financial Results Webcast
Charge Enterprises, Inc. (Nasdaq: CRGE) plans to host a public results webcast on May 10, 2023, during which Charge’s executive management will review and discuss the Company’s 2023 first quarter financial results.
Tiziana Life Sciences: A Biotech Microcap Revolutionizing Neurological Disorder Treatment with the Only Intranasal Fully Human anti-CD3 Monoclonal Antibody in Clinical Development
Tiziana Life Sciences Ltd is a biotechnology company focused on discovering and developing molecules for the treatment of human diseases in oncology and immunology.
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
NanoViricides, Inc. (NYSE Amer.: NNVC) a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India (“Karveer”).
SUNSHINE BIOPHARMA REPORTS FULL YEAR ENDED DECEMBER 31, 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal year ended December 31, 2022 and recent highlights.
Amesite and NAFEO Alliance Announce Expansion to Twelve Member Universities
Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announces today that new member universities have joined their collaborative alliance with the National Association for Equal Opportunity in...
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clin...